← Leaderboards
Xiaochen Bai
Ut Southwestern Medical Center
$5,235,262
Attributed
$7,342,563
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,342,563 · 6
By mechanism
R01$6,768,563 · 5
R35$574,000 · 1
Top collaborators
- Xuewu Zhang4 shared
- Chuo Chen3 shared
- Zhijian J Chen1 shared
- Xu Wu1 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Russell Alfred Debose-Boyd$14,724,021
- Jay D Horton$17,439,528
- William T Dauer$16,076,801
- Helen H. Hobbs$30,094,310
- Mike Henne$5,287,559
Others in their field
Other Emerging Leaders on “Structure”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$68,763,143
- Leonard Freedman · Leidos Biomedical Research, Inc.$67,827,589
- John Damon Chodera · Sloan-Kettering Inst Can Research$62,074,236
Research focus
StructureCryoelectron MicroscopyPlaySignal TransductionBindingCell MembraneMolecular ConformationResolutionMalignant NeoplasmsLigand BindingLigandsComplexLengthReceptorDimerFamilyIn VitroBiochemicalCell Surface ReceptorsLinkDimerizationLipidsHuman DiseaseDesign
Grant awards (16)
Novel regulatory mechanisms and agonists of STING$680,598
R01 · FY2025 · CA
Novel regulation and functions of TEAD-VGLL complex$680,594
R01 · FY2025 · CA
Novel endogenous and engineered activators of STING: from mechanisms to cancer therapy$642,739
R01 · FY2025 · CA · contact PI
Understanding general principles in receptor tyrosine kinase signaling through structural and functional studies$574,000
R35 · FY2025 · GM · contact PI
Novel regulatory mechanisms and agonists of STING$646,571
R01 · FY2024 · CA
Structural insights into the unique activation mechanisms of receptor tyrosine kinases$406,319
R01 · FY2024 · GM · contact PI
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State$352,600
R01 · FY2024 · GM · contact PI
Novel regulatory mechanisms and agonists of STING$680,598
R01 · FY2023 · CA
Structural insights into the unique activation mechanisms of receptor tyrosine kinases$406,319
R01 · FY2023 · GM · contact PI
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State$352,600
R01 · FY2023 · GM · contact PI
Structural insights into the unique activation mechanisms of receptor tyrosine kinases$406,319
R01 · FY2022 · GM · contact PI
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State$352,600
R01 · FY2022 · GM · contact PI
Structural insights into the unique activation mechanisms of receptor tyrosine kinases$406,075
R01 · FY2021 · GM · contact PI
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State$352,063
R01 · FY2021 · GM · contact PI
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State$51,580
R01 · FY2021 · GM · contact PI
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State$350,988
R01 · FY2020 · GM · contact PI